Hot Line:137-9521-9287
Location:Home » Anticancer Products » others




CAS#: 1972-08-3

Description: Dronabinol is a psychoactive compound extracted from the resin of Cannabis sativa. The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. This cannabinoid (CB) binds with high affinity to both the central CB1 receptor and the peripheral CB2 receptor, working primarily through these receptors, has diverse effects on perception, cognition, pain sensitivity, body temperature, the immune system, fetal development, and more.

Synonym: Dronabinol; Marinol; TETRAHYDROCANNABINOL; Delta9-Tetrahydrocannabinol; Deltanyne; Delta9-THC;Tetrahydrocannabinol, (6a-trans)-Isomer; Tetrahydrocannabinol, (6aR-cis)-Isomer; Tetrahydrocannabinol, (6aS-cis)-Isomer; Tetrahydrocannabinol, Trans Isomer; Tetrahydrocannabinol, Trans-(+-)-Isomer; Tetrahydrocannabinol, Trans-Isomer; THC;

IUPAC/Chemical Name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol

Dronabinol, purity > 98%, is not in stock, may be available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received.


Name: Dronabinol
CAS#: 1972-08-3
Chemical Formula: C21H30O2
Exact Mass: 314.22458
Molecular Weight: 314.46
Elemental Analysis: C, 80.21; H, 9.62; O, 10.18


Solid powder
>98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition:
Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).
Soluble in DMSO, not in water
Shelf Life:
>2 years if stored properly
Drug Formulation:
This drug may be formulated in DMSO
Stock Solution Storage:
0 – 4 C for short term (days to weeks), or -20 C for long term (months).



1: Jicha CJ, Lofwall MR, Nuzzo PA, Babalonis S, Elayi SC, Walsh SL. Safety of
oral dronabinol during opioid withdrawal in humans. Drug Alcohol Depend. 2015 Dec
1;157:179-83. doi: 10.1016/j.drugalcdep.2015.09.031. Epub 2015 Oct 9. PubMed
PMID: 26483357; PubMed Central PMCID: PMC4663169.

2: Elder JJ, Knoderer HM. Characterization of Dronabinol Usage in a Pediatric
Oncology Population. J Pediatr Pharmacol Ther. 2015 Nov-Dec;20(6):462-467. PubMed
PMID: 26766935.

3: Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, Nunes EV,
Bisaga A, Dakwar E, Carpenter KM, Sullivan MA, Choi JC. Dronabinol and lofexidine
for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Drug Alcohol Depend. 2015 Nov 27. pii: S0376-8716(15)01778-0. doi:
10.1016/j.drugalcdep.2015.11.025. [Epub ahead of print] PubMed PMID: 26711160.

4: Reichenbach ZW, Sloan J, Rizvi-Toner A, Bayman L, Valestin J, Schey R. A
4-week Pilot Study With the Cannabinoid Receptor Agonist Dronabinol and Its
Effect on Metabolic Parameters in a Randomized Trial. Clin Ther. 2015 Oct
1;37(10):2267-74. doi: 10.1016/j.clinthera.2015.07.023. Epub 2015 Aug 14. PubMed
PMID: 26283236.

5: Andries A, Frystyk J, Flyvbjerg A, Støving RK. Changes in IGF-I, urinary free
cortisol and adipokines during dronabinol therapy in anorexia nervosa: Results
from a randomised, controlled trial. Growth Horm IGF Res. 2015 Oct;25(5):247-52.
doi: 10.1016/j.ghir.2015.07.006. Epub 2015 Jul 29. PubMed PMID: 26248813.

6: Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN,
Levin FR, Carpenter KM, Mariani JJ, Nunes EV. The effects of dronabinol during
detoxification and the initiation of treatment with extended release naltrexone.
Drug Alcohol Depend. 2015 Sep 1;154:38-45. doi: 10.1016/j.drugalcdep.2015.05.013.
Epub 2015 Jul 8. PubMed PMID: 26187456; PubMed Central PMCID: PMC4536087.

7: Andries A, Gram B, Støving RK. Effect of dronabinol therapy on physical
activity in anorexia nervosa: a randomised, controlled trial. Eat Weight Disord.
2015 Mar;20(1):13-21. doi: 10.1007/s40519-014-0132-5. Epub 2014 Jun 3. PubMed
PMID: 24890912.

8: Hernandez SL, Sheyner I, Stover KT, Stewart JT. Dronabinol treatment of
refractory nausea and vomiting related to peritoneal carcinomatosis. Am J Hosp
Palliat Care. 2015 Feb;32(1):5-7. doi: 10.1177/1049909113504240. Epub 2013 Sep
19. PubMed PMID: 24052427.

9: Taylor GH, Schwaitzberg SD. The successful use of dronabinol for failure to
thrive secondary to intestinal dysmotility. Int J Surg Case Rep. 2015;11:121-3.
doi: 10.1016/j.ijscr.2015.04.036. Epub 2015 May 5. PubMed PMID: 25974259; PubMed
Central PMCID: PMC4446691.

10: de Vries M, van Rijckevorsel DC, Wilder-Smith OH, van Goor H. Dronabinol and
chronic pain: importance of mechanistic considerations. Expert Opin Pharmacother.
2014 Aug;15(11):1525-34. doi: 10.1517/14656566.2014.918102. Epub 2014 May 12.
Review. PubMed PMID: 24819592.

11: Issa MA, Narang S, Jamison RN, Michna E, Edwards RR, Penetar DM, Wasan AD.
The subjective psychoactive effects of oral dronabinol studied in a randomized,
controlled crossover clinical trial for pain. Clin J Pain. 2014 Jun;30(6):472-8.
doi: 10.1097/AJP.0000000000000022. PubMed PMID: 24281276; PubMed Central PMCID:

12: Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. Dronabinol for
the treatment of agitation and aggressive behavior in acutely hospitalized
severely demented patients with noncognitive behavioral symptoms. Am J Geriatr
Psychiatry. 2014 Apr;22(4):415-9. doi: 10.1016/j.jagp.2012.11.022. Epub 2013 Apr
15. PubMed PMID: 23597932.

13: Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA.
Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis
dependence. Ther Drug Monit. 2014 Apr;36(2):218-24. doi:
10.1097/FTD.0b013e3182a5c446. PubMed PMID: 24067260; PubMed Central PMCID:

14: Calik MW, Carley DW. Cannabinoid type 1 and type 2 receptor antagonists
prevent attenuation of serotonin-induced reflex apneas by dronabinol in
Sprague-Dawley rats. PLoS One. 2014 Oct 28;9(10):e111412. doi:
10.1371/journal.pone.0111412. eCollection 2014. PubMed PMID: 25350456; PubMed
Central PMCID: PMC4211887.

15: Farabi SS, Prasad B, Quinn L, Carley DW. Impact of dronabinol on quantitative
electroencephalogram (qEEG) measures of sleep in obstructive sleep apnea
syndrome. J Clin Sleep Med. 2014 Jan 15;10(1):49-56. doi: 10.5664/jcsm.3358.
PubMed PMID: 24426820; PubMed Central PMCID: PMC3869068.

16: Calik MW, Radulovacki M, Carley DW. Intranodose ganglion injections of
dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat. Respir
Physiol Neurobiol. 2014 Jan 1;190:20-4. doi: 10.1016/j.resp.2013.10.001. Epub
2013 Oct 11. PubMed PMID: 24121138; PubMed Central PMCID: PMC3880550.

17: Andries A, Frystyk J, Flyvbjerg A, Støving RK. Dronabinol in severe, enduring
anorexia nervosa: a randomized controlled trial. Int J Eat Disord. 2014
Jan;47(1):18-23. doi: 10.1002/eat.22173. Epub 2013 Sep 14. PubMed PMID: 24105610.

18: Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Gomez Cano M,
McManus D, Mallik S, Hobart J; CUPID investigator group. Effect of dronabinol on
progression in progressive multiple sclerosis (CUPID): a randomised,
placebo-controlled trial. Lancet Neurol. 2013 Sep;12(9):857-65. doi:
10.1016/S1474-4422(13)70159-5. Epub 2013 Jul 13. Review. PubMed PMID: 23856559;
PubMed Central PMCID: PMC3744749.

19: Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of
dronabinol and smoked marijuana in daily marijuana smokers.
Neuropsychopharmacology. 2013 Sep;38(10):1984-92. doi: 10.1038/npp.2013.97. Epub
2013 Apr 22. PubMed PMID: 23609132; PubMed Central PMCID: PMC3746706.

20: Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular
dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol.
2013 Sep;18(5):872-81. doi: 10.1111/j.1369-1600.2011.00427.x. Epub 2012 Jan 19.
PubMed PMID: 22260337; PubMed Central PMCID: PMC3335956.

Previous: Next: